Profile
Thomas Andrew Davis is former Chief Medical Officer for Genocea Biosciences, Inc., former Chief Medical Officer & Executive Vice President at Celldex Therapeutics, Inc. former Chief Medical Officer & Senior Vice President of AVANT Immunotherapeutics, Inc. and former Chief Medical Officer & VP-Clinical Development at Celldex Research Corp.
(both are subsidiaries of Celldex Therapeutics, Inc.), former Chief Medical Officer of Gadeta BV, former Chief Medical Officer for GenVec, Inc. and former Senior Director-Clinical Science at Medarex, Inc.
He received a doctorate and a graduate degree from Georgetown University and an undergraduate degree from The Johns Hopkins University.
Former positions of Thomas Andrew Davis
Companies | Position | End |
---|---|---|
GENOCEA BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 2022-05-19 |
Gadeta BV
Gadeta BV Medical SpecialtiesHealth Technology Gadeta BV discovers and develops novel cancer immunotherapies. It provides groundbreaking discoveries regarding the role of cell receptors in the broad of heamatological and solid tumor cells. The firm develops t-cells engineered to express a defined gamma delta, an anti- cancer product that eradicates tumors. The company was founded by Jurgen Kuball in 2015 and is headquartered in Utrecht, Netherlands. | Chief Tech/Sci/R&D Officer | 2018-03-31 |
CELLDEX THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2017-08-31 |
AVANT Immunotherapeutics, Inc.
AVANT Immunotherapeutics, Inc. Medical SpecialtiesHealth Technology AVANT Immunotherapeutics, Inc. is a biopharmaceutical company. Discovers, develops and commercializes vaccines and therapeutics that address various applications including cardiovascular, viral and bacterial diseases. The company markets Rotarix for rotavirus infection and Megan Egg and Megan Vac 1 for Salmonella infection in chicken. It's immunotherapeutic products include TP10 for cardiac bypass surgery and CETi for cholesterol management. The company develops various bacterial vaccines including CholeraGarde for cholera, Ty800 for typhoid fever and Injectable Anthrax for anthrax infection. AVANT Immunotherapeutics has various products in preclinical development stages which include ETEC for Enterotoxigenic E coli infection, Shigella for dysentery, campylobacter for campylobacter infection, Oral Anthrax and Plague vaccines and other food safety and animal health vaccines. AVANT Immunotherapeutics was organized in 1983 and is headquartered in Needham, MA. | Chief Tech/Sci/R&D Officer | 2008-09-30 |
Celldex Research Corp.
Celldex Research Corp. Miscellaneous Commercial ServicesCommercial Services Celldex Research Corp. engages in provision of biological research and development. The company is headquartered in Phillipsburg, NJ. | Chief Tech/Sci/R&D Officer | 2008-02-29 |
Training of Thomas Andrew Davis
The Johns Hopkins University | Undergraduate Degree |
Georgetown University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
GENOCEA BIOSCIENCES, INC. | Health Technology |
CELLDEX THERAPEUTICS, INC. | Health Services |
Private companies | 5 |
---|---|
Medarex, Inc.
Medarex, Inc. Miscellaneous Commercial ServicesCommercial Services Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey. | Commercial Services |
GenVec, Inc.
GenVec, Inc. Pharmaceuticals: MajorHealth Technology GenVec, Inc. operated as a clinical-stage gene delivery company, which engaged in the development of therapeutics and vaccines. The firm designs, tests, and manufactured adenoviral-based product candidates using its proprietary AdenoVerse platform. Its products included CGF166-Hearing Loss; GV2311-RSV Vaccine; and GV2207-HSV-2 Immunotherapeutic. The company was founded in December 1992 and was headquartered in Rockville, MD. | Health Technology |
AVANT Immunotherapeutics, Inc.
AVANT Immunotherapeutics, Inc. Medical SpecialtiesHealth Technology AVANT Immunotherapeutics, Inc. is a biopharmaceutical company. Discovers, develops and commercializes vaccines and therapeutics that address various applications including cardiovascular, viral and bacterial diseases. The company markets Rotarix for rotavirus infection and Megan Egg and Megan Vac 1 for Salmonella infection in chicken. It's immunotherapeutic products include TP10 for cardiac bypass surgery and CETi for cholesterol management. The company develops various bacterial vaccines including CholeraGarde for cholera, Ty800 for typhoid fever and Injectable Anthrax for anthrax infection. AVANT Immunotherapeutics has various products in preclinical development stages which include ETEC for Enterotoxigenic E coli infection, Shigella for dysentery, campylobacter for campylobacter infection, Oral Anthrax and Plague vaccines and other food safety and animal health vaccines. AVANT Immunotherapeutics was organized in 1983 and is headquartered in Needham, MA. | Health Technology |
Celldex Research Corp.
Celldex Research Corp. Miscellaneous Commercial ServicesCommercial Services Celldex Research Corp. engages in provision of biological research and development. The company is headquartered in Phillipsburg, NJ. | Commercial Services |
Gadeta BV
Gadeta BV Medical SpecialtiesHealth Technology Gadeta BV discovers and develops novel cancer immunotherapies. It provides groundbreaking discoveries regarding the role of cell receptors in the broad of heamatological and solid tumor cells. The firm develops t-cells engineered to express a defined gamma delta, an anti- cancer product that eradicates tumors. The company was founded by Jurgen Kuball in 2015 and is headquartered in Utrecht, Netherlands. | Health Technology |